HC Wainwright Reiterates “Neutral” Rating for RAPT Therapeutics (NASDAQ:RAPT)

HC Wainwright reissued their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research note published on Monday morning,Benzinga reports. HC Wainwright also issued estimates for RAPT Therapeutics’ Q4 2024 earnings at ($0.58) EPS, FY2024 earnings at ($2.56) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.63) EPS and FY2025 earnings at ($2.61) EPS.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company cut their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. UBS Group cut their target price on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research note on Monday, September 9th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research report on Wednesday, November 13th. Piper Sandler downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $8.00 to $2.00 in a report on Monday, November 11th. Finally, JPMorgan Chase & Co. downgraded RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $9.50.

RAPT Therapeutics Stock Up 9.8 %

Shares of RAPT Therapeutics stock opened at $1.23 on Monday. RAPT Therapeutics has a 12-month low of $1.00 and a 12-month high of $27.35. The firm has a market capitalization of $43.00 million, a PE ratio of -0.44 and a beta of 0.33. The stock’s fifty day moving average is $1.79 and its 200-day moving average is $2.60.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. Analysts expect that RAPT Therapeutics will post -2.73 EPS for the current year.

Institutional Trading of RAPT Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Barclays PLC increased its position in RAPT Therapeutics by 277.2% in the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after purchasing an additional 29,195 shares during the last quarter. Readystate Asset Management LP bought a new stake in shares of RAPT Therapeutics in the 3rd quarter valued at approximately $36,000. Los Angeles Capital Management LLC increased its holdings in RAPT Therapeutics by 138.1% in the third quarter. Los Angeles Capital Management LLC now owns 201,439 shares of the company’s stock worth $405,000 after buying an additional 116,853 shares during the last quarter. Exchange Traded Concepts LLC raised its position in RAPT Therapeutics by 244.7% during the third quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company’s stock valued at $179,000 after acquiring an additional 63,235 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in RAPT Therapeutics by 176,725.0% in the second quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock valued at $2,157,000 after acquiring an additional 706,900 shares during the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.